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Abstract
Background: Uncovering the molecular mechanism underlying expansion of hematopoietic stem
and progenitor cells is critical to extend current therapeutic applications and to understand how
its deregulation relates to leukemia. The characterization of genes commonly relevant to stem/
progenitor cell expansion and tumor development should facilitate the identification of novel
therapeutic targets in cancer.
Methods: CD34+/CD133+ progenitor cells were purified from human umbilical cord blood and
expanded in vitro. Correlated molecular changes were analyzed by gene expression profiling using
microarrays covering up to 55,000 transcripts. Genes regulated during progenitor cell expansion
were identified and functionally classified. Aberrant expression of such genes in cancer was
indicated by in silico SAGE. Differential expression of selected genes was assessed by real-time PCR
in hematopoietic cells from chronic myeloid leukemia patients and healthy individuals.
Results: Several genes and signaling pathways not previously associated with ex vivo expansion of
CD133+/CD34+ cells were identified, most of which associated with cancer. Regulation of MEK/
ERK and Hedgehog signaling genes in addition to numerous proto-oncogenes was detected during
conditions of enhanced progenitor cell expansion. Quantitative real-time PCR analysis confirmed
down-regulation of several newly described cancer-associated genes in CD133+/CD34+ cells,
including  DOCK4  and  SPARCL1  tumor suppressors, and parallel results were verified when
comparing their expression in cells from chronic myeloid leukemia patients
Conclusion: Our findings reveal potential molecular targets for oncogenic transformation in
CD133+/CD34+ cells and strengthen the link between deregulation of stem/progenitor cell
expansion and the malignant process.
Background
Hematopoiesis is a tightly regulated process with impor-
tant clinical and therapeutic implications. Understanding
how expansion of hematopoietic stem and progenitor
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cells is regulated may reveal molecular mechanisms asso-
ciated with leukemogenesis. Another practical goal of this
knowledge is to devise techniques for expanding the
amount of such progenitors from human umbilical cord
blood (UCB), in sufficient levels for allogeneic transplants
in adults suffering from hematological malignancies
[1,2].
The CD133 antigen has been considered as a new marker
of primitive hematopoietic stem cells (HSC) capable of
supporting hematopoiesis both in vitro and in vivo [3,4].
Circulating stem cells in UCB characterized by co-expres-
sion of CD34 and CD133 markers display a certain degree
of plasticity, which expands their prospective therapeutic
use [5]. This subpopulation of CD133+/CD34+ cells also
shows higher engraftment in NOD/SCID mice than
CD133-/CD34+ cells [6] and clinical-scale isolation of
functional CD133+ cells can be performed from cryopre-
served UCB samples [7].
Several recent studies have focused on conditions for ex
vivo expansion of CD133+ cells [8-10]. Nonetheless, few
studies have addressed potential biosafety concerns such
as chronic effects and tumorigenesis. Indeed, tumors may
arise from the neoplastic transformation of normal stem
cells, supported by the fact that some signaling pathways
known to be involved in stem cell self-renewal and prolif-
eration of progenitors are also associated with cancer [11].
Although expression profiling studies have been con-
ducted comparing CD133+ with their CD133- counter-
parts in attempt to identify "stemness"-related genes [12-
15], the molecular events associated with expansion of
these primitive progenitors is still poorly described.
Mutations in normal somatic stem and progenitor cells
leading to deregulation of their physiological programs is
thought to increase their predisposition to tumor devel-
opment. Under this cancer stem cell hypothesis view-
point, the identification of genes commonly relevant to
stem/progenitor cell and tumor biology should facilitate
the development of novel therapeutic approaches in can-
cer.
In this work, we report conditions for basal and high yield
in vitro expansion of a CD133+/CD34+ subset of progen-
itor cells from human UCB stimulated by estradiol, a hor-
mone involved in both normal cell proliferation and
development of cancer. A detailed molecular characteriza-
tion of such processes is provided from a genomic per-
spective. Overlapping groups of genes and signaling
pathways involved in both progenitor expansion and can-
cer development were identified, including newly
described tumor suppressor genes of great therapeutic
interest.
Results
Expansion of CD133+ and CD34+ cells from UCB
Flow cytometry analysis revealed that most CD34+ cells
(82 ± 13%) also express CD133, a primitive human HSC
marker [see Additional file 1]. Upon cultivation in a
defined medium supplemented with growth factors (SCF,
IL3, IL6, and Flt3-ligand), the absolute amount of
CD133+ and CD34+ cells was estimated after 7, 14 and 21
days. Highest increment in CD133+/CD34+ cell number
occurred at day 7 (10.0 ± 1.1 fold). The amount of more
committed CD133-/CD34+ cells also increased, with a
maximum of 5.5 ± 0.9 fold observed at day 14. At the
same culture day, a robust increment (141.9 ± 16.5 fold)
in primitive CD133+/CD34- stem cell subset was detected
(Fig. 1A).
Under the same time-frame, higher expansion of these
three cell populations was obtained when cells were
treated with 10 nM E2. Total amounts of CD133+/CD34+
(at day 7), CD133-/CD34+ (at day 14) and CD133+/
CD34- (at day 14) cells were 18.7 ± 1.4, 9.2 ± 1.9, and
181.8 ± 20.4 fold higher in the presence of E2, respec-
tively, than at day 1. The CD133+ cells are rare primitive
stem cells usually representing less then 1% of the total
mononuclear cell fraction. In addition to increased cell
number, higher proportion of CD133+ cells were verified
in 7-day cultures, particularly in the presence of E2 (Fig.
1B).
In order to determine whether these UCB stem cells
retained their function after expansion, their clonogenic
activity was examined in vitro. The amount of CFU of mye-
loid and endothelial type was increased by a factor of 100
and 20, respectively, after seven days in basal growth
medium (SCF, IL3, IL6, and Flt3-ligand only). Such incre-
ment was enhanced nearly two fold after addition of 10
nM E2 (Fig.1C).
Genes involved in abrogation of CD133+/CD34+ cell 
quiescence
With the purpose of defining the pool of transcripts active
in UCB CD133+/CD34+ stem cells, we performed a
microarray hybridization using a platform containing
more than 55,000 oligonucleotide probes representing all
annotated human genes to date. Description of the bioar-
rays used is constantly updated by the manufacturer at the
GEO database under the accession numbers GPL2895 and
GPL2891. The starting total RNA used in the microarray
hybridizations was extracted from freshly isolated, non-
cultivated, CD133+/CD34+ cells, immediately after their
purification from UCB. A typical microarray-based analy-
sis of gene expression was applied in order to clarify the
molecular events associated with their ex vivo expansion,
under basal growth conditions.Cancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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A total of 851 up-regulated genes and 991 down-regulated
genes were found, as a consequence of expansion for
seven days in basal growth medium (day-7 vs. day-0 com-
parison). A myriad of biological processes and molecular
functions could be related to these differentially expressed
genes [see Additional file 1]. However, the overall repre-
sentation of genes and corresponding annotated func-
tions in the entire human genome may confer a bias when
grouping genes based on functional similarity. Further-
more, a single gene may belong to multiple categories.
Therefore, a statistical test was applied to find functional
categories over-represented in the lists of differentially
expressed genes, in attempt to distinguish processes and
functions specifically associated with cell expansion from
those present due to random chance.
Such classification strategy revealed that the list of up-reg-
ulated genes is specially enriched in genes functioning in
primary metabolism (e.g. RNA synthesis and processing,
protein metabolism, and ATP biosynthesis), while tran-
scription regulation and signal transduction are over-rep-
resented among the down-regulated genes. Figure 2
summarizes the number of enriched genes, their corre-
sponding molecular functions, and respective P-values for
In vitro expansion of stem and progenitor cells from UCB cultivated in the presence or absence of estradiol Figure 1
In vitro expansion of stem and progenitor cells from UCB cultivated in the presence or absence of estradiol. (A) Fold increment 
in CD133+/CD34+, CD133-/CD34+, and CD133+/CD34- cell number after 7, 14, and 21 days in culture. (B) Flow cytometry 
analysis showing percentage of mononucleated cells expressing CD133 prior to and after culturing for 7 days. Positive and iso-
type controls are provided in supplemental figure S2. (C) Functional clonogenic assay based on the frequency of colony forming 
units (CFU). Data correspond to fold expansion of myeloid and endothelial progenitors at culture day 7. GF = basal medium 
supplemented with growth factors only (SCF, IL3, IL6, and Flt3-ligand); E2 = medium supplemented with growth factors plus 10 
nM estradiol. Statistical significance for GF vs. E2 comparisons: * P < 0.01, **P < 0.001.Cancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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functional association, indicating that expansion of
CD133+/CD34+ cells involves an intense metabolic activ-
ity and regulation of gene expression at all levels. The list
of differentially expressed genes classified by enriched
functional category is provided [see Additional file 2].
The largest enriched functional group consisted of over
100 transcription factors that were down-regulated during
the basal growth condition tested. Most of them code for
zinc finger (41%) and homeobox (20%) proteins, with
many functioning in development control. The up-regu-
lated group of genes was also enriched in transcription
factors, mainly zinc fingers (45%) and basal transcription
factors (10%) required for general transcription.
Enhanced CD133+/CD34+ cell expansion correlates with 
regulation of genes abnormally expressed in cancer
Since superior ex vivo expansion of CD133+/CD34+ cells
was observed when cultivated in the presence of E2, the
next step aimed at identifying the early on genes and reg-
ulatory pathways possibly accounting for such effect. The
gene enrichment and functional classification analysis of
a set of 394 genes showing greater than two fold differ-
ences in expression after 1h-treatment with 10 nM E2
(222 up- and 172 down-regulated), revealed that tran-
scription regulation, protein modification/degradation,
and signal transduction are over-represented classes in
both up- and down-regulated gene lists (Table 1). In the
transcription factor category, zinc fingers persisted as
majority (60% of down-regulated and 39% of up-regu-
lated genes). Almost half of the up-regulated zinc fingers
are transcription repressors containing the CRAB domain,
suggesting a tight control of gene expression.
One common trait observed for most genes comprising
the over-represented functional classes regulated in
CD133+/CD34+ cells by E2 is the abnormal expression in
tumors. As shown in table 1, from the list of enriched
functional categories, 82% of the up-regulated genes and
87% of the down-regulated genes are also deregulated in
cancer, several of which having a role in tumorigenesis,
according to in silico SAGE and literature data mining.
Another strategy used to unraveling processes and func-
tions related with expansion of CD133+/CD34+ stem
cells by E2 was to assess the regulatory signaling pathways
represented among the differentially expressed genes.
Table 2 lists all signaling pathways and corresponding
gene members found in such analysis. The data for genes
differentially expressed in the E2 treatment or in basal
growth medium alone are shown in parallel. From the 10
major regulatory pathways identified, Calcium and MAPK
signaling were the ones represented by the largest number
of members (> 10). In the MAPK signaling, members of
the JNK/p38 MAPK pathway were down-regulated in cells
expanded in basal medium and cells under E2 treatment,
while members of the MEK/ERK pathway were up-regu-
lated only in E2-treated cells. Members of the Notch and
Wnt pathways were regulated solely by the basal expan-
sion condition, while NF-kappaB (represented by IRAK2
and BCL10) and Sonic Hedgehog (represented by GLI2)
were found regulated only after E2 treatment.
Novel genes involved in CD133+/CD34+ cell expansion 
with parallel expression pattern in chronic myeloid 
leukemia
Several of these cancer-associated genes identified as
being regulated during CD133+/CD34+ cell expansion
are new and still not fully functionally characterized in the
literature, such as MS4A6A,  FNBP3,  DOCK4, and
SPARCL1. Differential expression of these genes, in addi-
tion to other identified early E2-regulated genes display-
ing aberrant expression in tumors was confirmed in
CD133+/CD34+ cells by quantitative real-time PCR
(Fig.3), validating the microarray data. To further examine
a possible connection with tumorigenesis, differential
expression of the abovementioned genes was examined in
the mononuclear cell fraction of healthy volunteers and
chronic myeloid leukemia (CML) patients. Significant dif-
ferences in expression were found for DOCK4,  GLI2,
BCL10, SPARCL1, MS4A6A, and FNBP3 (Fig.4).
Discussion
Knowledge of the mechanisms controlling stem/progeni-
tor cell expansion is critical to broaden current therapeutic
application for hematopoietic reconstitution and to
understand how its deregulation may lead to pathological
conditions. To address this issue, we first examined the
extent of expansion in a defined medium for distinct
stem/progenitor cell subsets. Highest increment in
amount was detected for CD133+/CD34- cells, reaching
over 100 fold expansion after 14 days. However, most of
the CD133+ cells also expressed the membrane protein
CD34. This CD133+/CD34+ cell subset accounted for the
majority of the cells in culture and exhibited a maximum
expansion of 10 fold after seven days. In all cases, addition
of E2 in the culture medium resulted in improved expan-
sion and increased amount of clonogenic cells.
Substantial changes in the CD133+/CD34+ cell's tran-
scriptome were detected following expansion in basal
growth medium, characterized by differential expression
of hundreds of genes. Nearly half of these genes was up-
regulated and the other half down-regulated. Using an
ontology enrichment analysis, we identified biological
processes significantly associated to this expansion condi-
tion. There was a striking activation of the cellular primary
metabolism, marked by up-regulation of protein and
energy biosynthesis, suggesting abrogation of quiescence,
a state characteristic of adult stem cells [16]. In agreementCancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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with this notion, 82 of the up-regulated genes were iden-
tified with a function in cell cycle, including proliferating
cell nuclear antigen (PCNA), Cyclins A2 and B1, cell divi-
sion cycle genes (Cdc2, Cdc20, Cdc25C, and Cdc28), and
cyclin-dependent kinases (CDK4, CDK5, and CDK8).
Another evidence for quiescence abrogation is the down-
regulation of two members of the growth arrest and DNA
damage 45 family, GADD45-beta and GADD45-gamma,
known to be activated during stress conditions. These
nuclear proteins are ubiquitously expressed in all tissues
where they are involved in maintenance of genomic sta-
bility, DNA repair, and suppression of cell growth
through interaction with cell cycle proteins. Transcrip-
tional silencing of GADD45-gamma due to promoter
hypermethylation has been recently reported in several
tumor cell lines and this epigenetic inactivation correlated
with tumorigenesis [17]. In the hematopoietic environ-
ment, GADD45 deletion has also been shown to support
CD4+ T cell proliferation and resistance to apoptosis [18].
Expression of GADD45 genes is known to induce apopto-
sis via activation of the JNK and p38 MAPK pathway [19].
Accordingly, down-regulation of GADD45-beta and
GADD45-gamma in CD133+/CD34+ cells during basal
expansion condition was associated with down-regula-
tion of MAPK13  (p38-delta) as well as of c-JUN  and
Gene-Enrichment and Functional Annotation Analysis Figure 2
Gene-Enrichment and Functional Annotation Analysis. Main functional categories of differentially expressed genes associated 
with expansion of CD133+/CD34+ cells in basal medium supplemented with growth factors (SCF, IL3, IL6, and Flt3-ligand). 
Statistical significance: P-values = 0.001 for all comparisons, according to the Fisher Exact Test for ontology enrichment analy-
sis.Cancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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Table 1: Genes differentially expressed in CD133+/CD34+ cells after 1h-treatment with 10 nM estradiol. Only those genes and their 
corresponding functional classes found significantly associated with the estradiol treatment are shown (P-values = 0.001, according to 
the Fisher Exact Test for enrichment analysis). Expression data is given as fold change from control, with negative values indicating 
repression. Additional information on deregulation in cancer and functional evidence of role in tumorigenesis is provided based on in 
silico SAGE and literature datamining*, respectively.
ACCESSION No. FOLD CHANGE DEREGULATED IN 
CANCER
FUNCTION IN 
TUMORIGENESIS
DESCRIPTION
UP-REGULATED GENES
TRANSCRIPTION(P-value = 1.3E-17)
NM_003426 2,3 yes ND zinc finger protein 74 (Cos52)
AK024438 2.1 yes ND hypothetical protein FLJ38705
NM_005419 2.3 yes yes signal transducer and activator of transcription 2, 113 kDa
NM_032329 2.5 yes yes inhibitor of growth family, member 5
NM_005239 2.3 yes yes v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) (ETS2)
NM_032433 2.1 yes ND zinc finger protein 333
AK024763 2.1 yes ND small nuclear RNA activating complex, polypeptide 5, 19 kDa
NM_006732 2.2 yes yes FBJ murine osteosarcoma viral oncogene homolog B (FOSB)
AK024514 2.6 yes yes suppressor of zeste 12 homolog (Drosophila)
NM_000901 2.6 yes ND nuclear receptor subfamily 3, group C, member 2
NM_000209 2.1 yes yes insulin promoter factor 1, homeodomain transcription factor
NM_003073 2.3 yes yes SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily b, member 1 (SMARCB1)
NM_022465 2.0 yes ND zinc finger protein, subfamily 1A, 4 (Eos)
NM_006509 2.0 yes yes v-rel avian reticuloendotheliosis viral oncogene homolog (RELB)
BC032246 2.1 yes ND zinc finger protein 44 (KOX 7)
AK021493 2.2 yes ND cAMP responsive element binding protein 5
AF052094 2.7 yes ND endothelial PAS domain protein 1
AK025453 2.0 yes yes prospero-related homeobox 1
BI861540 2.2 yes ND PBX/knotted 1 homeobox 2
NM_005384 2.7 yes ND nuclear factor, interleukin 3 regulated
NM_145165 2.2 yes ND churchill domain containing 1
NM_144690 2.2 no ND zinc finger protein 582
NM_006713 2.6 yes ND SUB1 homolog (S. cerevisiae)
PROTEIN MODIFICATION (P-value = 1.44E-7)
AF038042 2.1 yes yes BRCA1 associated RING domain 1
NM_007218 2.2 yes yes ring finger protein 139
NM_024686 2.4 yes ND tubulin tyrosine ligase-like family, member 7
AB011116 2.2 yes ND mahogunin, ring finger 1
AF070538 2.5 yes ND tripartite motif-containing 3
NM_024787 2.9 yes ND ring finger protein 122
AF176705 2.2 yes ND F-box protein 10
NM_023079 2.0 yes ND Ubiquitin-conjugating enzyme E2Z (putative)
G-PROTEIN COUPLED RECEPTOR(P-value = 3.57E-8)
NM_002386 2.3 yes ND melanocortin 1 receptor (alpha melanocyte stimulating hormone 
receptor)Cancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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NM_002980 2.8 yes ND secretin receptor
AF303373 2.1 no ND olfactory receptor, family 4, subfamily D, member 2
NM_005314 2.4 yes ND gastrin-releasing peptide receptor
NM_030774 2.0 no ND olfactory receptor, family 51, subfamily E, member 2
NM_004248 2.2 no ND G protein-coupled receptor 10
M76676 2.3 yes ND G protein-coupled receptor 135
DOWN-REGULATED GENES
TRANSCRIPTION (P-value = 2.44E-7)
NM_030381 -2.7 yes yes GLI-Kruppel family member GLI2
NM_005920 -2.2 yes yes MADS box transcription enhancer factor 2, polypeptide D (myocyte 
enhancer factor 2D)
AF146694 -4.4 yes ND PHD finger protein 7
NM_017831 -2.6 no ND ring finger protein 125
NM_003316 -2.0 yes ND tetratricopeptide repeat domain 3
NM_004234 -2.2 no ND zinc finger protein 235
U69127 -2.5 yes ND far upstream element (FUSE) binding protein 3
NM_002466 -3.1 yes ND v-myb myeloblastosis viral oncogene homolog (avian)-like 2 (MYBL2)
NM_001166 -2.1 yes yes baculoviral IAP repeat-containing 2
AA001334 -2.7 yes ND zinc fingers and homeoboxes 2
NM_016166 -2.2 yes ND protein inhibitor of activated STAT, 1
PROTEOLYSIS AND PEPTIDOLYSIS (P-value = 5.75E-9)
NM_003343 -2.0 yes ND ubiquitin-conjugating enzyme E2G 2 (UBC7 homolog, yeast)
NM_023038 -2.6 yes ND ADAM metallopeptidase domain 19
NM_005800 -2.5 yes ND Ubiquitin specific peptidase like 1
NM_032582 -3.6 yes ND ubiquitin specific protease 32
NM_001335 -2.2 yes ND cathepsin W (lymphopain)
NM_000930 -2.0 yes ND plasminogen activator, tissue
PROTEIN KINASE CK2 ACTIVITY(P-value = 2.1E-10)
NM_006482 -2.8 yes ND dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2
AF086179 -2.0 yes yes cyclin-dependent kinase 6
NM_005406 -2.8 yes yes Rho-associated, coiled-coil containing protein kinase 1
D50683 -2.0 yes yes transforming growth factor, beta receptor II (70/80 kDa)
NM_003954 -2.5 no ND mitogen-activated protein kinase kinase kinase 14
NM_014326 -2.5 yes ND death-associated protein kinase 2
Only those genes and their corresponding functional classes found significantly associated with the estradiol treatment are shown (P-values = 0.001, according to the Fisher 
Exact Test for enrichment analysis). Expression data is given as fold change from control, with negative values indicating repression. Additional information on deregulation in 
cancer and functional evidence of role in tumorigenesis is provided based on in silico SAGE and literature datamining*, respectively.
* Literature data mining was performed in batch by the DAVID 2.1 tool. ND = function not determined at the time of analysis.
Table 1: Genes differentially expressed in CD133+/CD34+ cells after 1h-treatment with 10 nM estradiol. Only those genes and their 
corresponding functional classes found significantly associated with the estradiol treatment are shown (P-values = 0.001, according to 
the Fisher Exact Test for enrichment analysis). Expression data is given as fold change from control, with negative values indicating 
repression. Additional information on deregulation in cancer and functional evidence of role in tumorigenesis is provided based on in 
silico SAGE and literature datamining*, respectively. (Continued)Cancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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MEF2C, two target transcription factors of the p38/JNK
pathway. The list of down-regulated genes also included
39 genes involved in apoptosis, among which members of
the TNF receptor superfamily (TNFRSF9, TNFRSF21, and
TNFRSF25) and related proteins (TNFAIP3 and TRAF4),
suggesting lower susceptibility to the apoptotic extrinsic
pathway.
In connection with the activation of primary metabolism,
signal transduction was another biological process signif-
icantly associated to the basal expansion of CD133+/
CD34+ cells. A specific analysis revealed an intricate mod-
ulation and interaction of regulatory signaling pathways,
favoring proliferation over differentiation. Under basal
growth conditions, the insulin and TGF-beta pathways
were mostly down-regulated, implicating in inhibition of
glycogen storage and organogenesis. While glycogenesis is
linked to energy biosynthesis, inhibition of TGF-beta sig-
naling is coherent with the observed down-regulation of
154 genes involved in development, 89 of them function-
ing specifically in organogenesis, mostly neurogenesis,
hematopoiesis, and general cell differentiation. Further-
more, up-regulation of a gene coding PIK3C2B, a specific
isoform of phosphoinositide 3-kinase, indicate stimula-
tion of the AKT/PKB survival signaling, connecting the
JAK-STAT and Phosphatidylinositol pathways.
Consistent with the literature, DKK4, an inhibitor of the
Wnt pathway, was found down-regulated in cells
expanded in basal growth condition, supporting the
involvement of such pathway in expansion of hematopoi-
etic progenitors [20]. A transcription activator of the CSL
family acting downstream the Notch signaling, RBPSUH,
was also found exclusively up-regulated under the same
expansion condition. A recent study with stem/progenitor
cells of the small intestine demonstrated that conditional
removal of RBPSUH, or blockade of the Notch pathway,
converts proliferative undifferentiated crypt progenitors
into postmitotic goblet cells in a concerted process with
the Wnt pathway [21]. More recently, JAG1, a Notch lig-
and, has been reported to be an evolutionarily conserved
target of the Wnt signaling pathway and a mediator of the
Wnt-induced self-renewal of HSC derived from embry-
onic cells [22]. Down-regulation of Notch leads to accel-
erated differentiation of HSC in vitro and depletion of
HSC in vivo, but does not seem critical for HSC entry into
the cell cycle [23].
When CD133+/CD34+ cells were enforced to proliferate
by treatment with E2, the major circulating ovarian ster-
Relative gene expression levels after 1h-treatment with 10  nM estradiol Figure 3
Relative gene expression levels after 1h-treatment with 10 
nM estradiol. Transcript levels were quantified by real-time 
PCR in CD133+/CD34+ cells either with or without estra-
diol (control). Data are expressed as log2 of fold change. 
Negative values indicate repression. Statistical significance: P 
< 0.001 for all comparisons.
Table 2: Regulatory signal transduction pathways and corresponding gene members found differentially expressed during expansion of 
CD133+/CD34+ cells. 
Signaling Pathway Control vs. GF GF vs. E2
Up-regulated Down-regulated Up-regulated Down-regulated
Calcium GNAQ, GSD VI PDGFB, ADRA1B, ERBA1, 
CACNA1I, PLCD3, PTK2B
CACNA1G, CACNA1D, 
ADORA2A, GRPR
ADCY3, CACNA1I, 
CACNA1H
Hedgehog ---G L I 2
Insulin GSD VI IRS4 PRKAG3 -
Jak-STAT PIK3C2B, IL2R, IL5RA CNTF, IL2RG, IFNGR2, IL23A STAT2, CTNF PIAS1, CTF1
MAPK - PDGFB, MAPK13, JUN, 
MEF2C, FGF6
RPS6KA1, PLA2G10 MAPKAPK3, ARRB1, FLNC, 
MAP3K14, TGFBR2
NF-Kappa B ---B C L 1 0 ,  I R A K 2
Notch R B P S U H ---
Phosphatidyl inositol PIK3C2B PLCD3 CDS1, DGKE, SYNJ1 CSNK1G2
TGF-Beta - INHBA, SMAD7 E2F4 ROCK1, TGFBR2
Wnt -D K K 4 --
(Control = freshly isolated cells without cultivation; GF = cells expanded for seven days in basal growth medium; E2 = cells expanded for seven days 
in basal growth medium plus 1h-treatment with 10 nM estradiol).Cancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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oid with known mitogenic effects, up-regulation of
RPS6KA1 and PLA2G10, two members of the MEK/ERK
pathway, and down-regulation of GLI2, a member of the
Hedgehog pathway, were verified. Activation of the
Hedgehog signaling pathway has been correlated to mat-
uration of hematopoietic progenitors and neuronal differ-
entiation of mesenchymal stem cells [24,25], whereas
constitutive activation of the MEK/ERK pathway stimu-
lates proliferation of erythroid progenitors and blocks
their differentiation [26].
Aberrant activation of Wnt, MEK/ERK, and Notch signal-
ing pathways is known to contribute to the pathogenesis
of myeloid leukemias and acute T-cell lymphoblastic
leukemias and lymphomas [27,28]. Therefore, it seems
reasonable to assume that deregulation of stem/progeni-
tor cell expansion is an important factor leading to tumor-
igenesis. While transient and controlled changes in the
expression of specific genes may contribute to stem/pro-
genitor cell maintenance and/or expansion, any event
(e.g. mutations, chromosome deletions or duplications)
allowing such changes to become permanent could also
contribute to neoplastic transformation. In agreement
with this concept, a very recently study by Toren et al. [15]
identified a group of growth factor receptors and tran-
scription factors differentially expressed in CD133+ cells
that are mutated in hematological malignancies.
In our model of E2-enhanced expansion of CD133+/
CD34+ cells, almost 400 genes displayed immediate
response to E2 and are likely involved in the propagation
of its biological effect. Although enhanced progenitor cell
expansion was detected under E2 treatment, such differ-
entially expressed genes identified in CD133+/CD34+
cells and their corresponding molecular process may also
be partially involved with other effects of E2, not
addressed in this work. Transcription, post-translational
modification and signal transduction were the molecular
process significantly associated with the E2 treatment,
according to an ontology enrichment analysis. Interest-
ingly, more than 80% of the genes comprising these over-
represented functional classes display abnormal expres-
sion in several tumor types. While some of these genes
have been reported to be involved in tumorigenesis, oth-
ers are still poorly described in the literature such as
MS4A6A, which codes for a signal transduction protein of
the MS4A family [29], FNBP3, a gene encoding another
signaling protein of the Rho-related pathway [30], and
IRAK2, a gene disrupted in HBV-induced hepatocellular
carcinomas [31]. Proto-oncogenes typically associated
with hematological malignancies, however, were not
over-represented.
Down-regulated genes in E2-treated CD133+/CD34+ cells
also included the newly characterized tumor suppressor
genes DOCK4, a member of the CDM gene family, and
SPARCL1, which encodes an extracellular matrix-associ-
ated glycoprotein. Both genes are down-regulated in can-
cers as a result of missense mutations or chromosomal
deletions [32,33]. While DOCK4 regulates formation of
cellular junctions and is disrupted in prostate and ovarian
cancers,SPARCL1 acts as a negative regulator of cell prolif-
eration and its down-regulation is detected in prostate,
colon, and non-small cell lung carcinomas [32,34,35].
Thus far, differential expression of DOCK4 and SPARCL1
had never been associated to CD133+/CD34+ cell expan-
sion or leukemias. Notably, when examining DOCK4 and
SPARCL1 expression in CML patients, we found that both
genes were also down-regulated compared to healthy
individuals, supporting a potential link between deregula-
tion of hematopoietic stem/progenitor cell expansion and
the malignant process. Due to their involvement in cancer
as a consequence of permanently aberrant expression,
pre-clinical studies assessing safety of stem/progenitor cell
expansion protocols for therapeutic application are highly
demanded. Nevertheless, the potential role of DOCK4
Expression levels of DOCK4, SPARCL1, BCL10, GLI2, MS4A6A,  and FNBP3 genes in healthy individuals (control) and chronic  myeloid leukemia patients Figure 4
Expression levels of DOCK4, SPARCL1, BCL10, GLI2, MS4A6A, 
and FNBP3 genes in healthy individuals (control) and chronic 
myeloid leukemia patients. Total RNA was extracted from 
purified mononuclear cells from peripheral blood samples. 
Transcript levels were quantified by real-time PCR and 
results are given as normalized gene expression. Horizontal 
bars indicate median expression values. Statistical signifi-
cance: P < 0.001 for DOCK4; P < 0.01 for SPARCL1, BCL10, 
and GLI2; P < 0.05 for MS4A6A and FNBP3.Cancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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and SPARCL1 as targets for oncogenic transformation in
adult progenitor cells remains to be confirmed.
Conclusion
In summary, our findings indicate that quiescence abroga-
tion of CD133+/CD34+ cells specifically involves regula-
tion of transcription factors functioning in primary
metabolism and development, as well as a concerted acti-
vation of genes from the Wnt, AKT/PKB, and Notch sign-
aling pathways. Superior expansion of CD133+/CD34+
cells however, introduces the risk of proto-oncogene regu-
lation. Our E2-enhanced cell expansion model was char-
acterized by the early activation of genes belonging to the
MEK/ERK survival pathway and a remarkable regulation
of multiple cancer-associated genes. Several genes not pre-
viously related to CD133+/CD34+ cell expansion were
identified, some of which known to have tumor suppres-
sor activities. Complemented by further studies, we
believe that such strategy may help elucidate molecular
mechanisms involved in expansion and neoplastic trans-
formation of stem/progenitor cells. Ultimately, new ther-
apeutic interventions in leukemias could be pursued.
Methods
Cell purification and culture
Human UCB was collected with informed consent
approved by the Internal Review Board of the Albert Ein-
stein Hospital (n = 5). CD133+ and CD34+ cells were
purified by immunomagnetic separation with MiniMACS
kit (Miltenyi Biotech), following the manufacturer's pro-
tocol. Cells were cultivated in Stem Pro medium (Gibco/
BRL), supplemented with 2 mM L-glutamine, 50 U/mL
penicillin, 50 μg/mL streptomycin, 50 ng/mL Flt-3 ligand,
10 ng/mL interleukin (IL)-3, 10 ng/mL IL-6, and 50 ng/
mL stem cell factor, in a humidified atmosphere at 37°C
and 5% CO2. Cell growth was monitored either with or
without addition of 10 nM 17-beta-Estradiol (E2) in the
media. This E2 concentration was defined based on previ-
ous dose response experiments by in vitro assays, as
described below.
Ex Vivo Expansion
The amount of CD133+ and CD34+ cells was analyzed on
days 0, 7, 14, and 21, by flow cytometry. Clonogenic
assays were performed on days 0 and 7. Briefly, for mye-
loid cell colonies, 5 × 103 CD133+/CD34+ cells were sus-
pended in 1 mL of semisolid methylcellulose medium
supplemented with 10% FCS, 1% bovine serum albumin
(BSA), 2 mM L-glutamine, 0.5 mM 2-mercaptoethanol,
10 ng/mL IL-3, 10 ng/ml IL-6, 50 ng/mL stem cell factor,
3 U/mL erythropoietin (StemCell Technologies) and cul-
tivated as above. Total colony forming units (CFUs) were
scored microscopically after 14 days (sum of CFU-Mix,
BFU-E, and CFU-GM). Endothelial cell colony forming
units were analyzed in 1 mL of semisolid methylcellulose
medium supplemented with 50 ng/mL VEGF, 50 ng/mL
SCF, and 5 ng/mL FGF (Stem Cells Technologies), accord-
ing to the manufacturer's protocol, and scored as above.
Flow Cytometry
Cells were incubated with monoclonal antibodies to
human antigens CD14 (FITC), CD34 (PE), CD45 (PerCP
Cy-5.5), and CD133 (APC; Myltenyi Biotec), with respec-
tive isotype controls IgG2a (FITC), IgG1 (PE), IgG1
(PerCP Cy-5.5), and IgG1 (APC) (Becton Dickinson), at
4°C for 30 minutes. Fluorescent cellular events were
acquired on the FACSAria flow cytometer and analyzed
with FacsDiva software (Becton Dickinson).
Microarray hybridization
Gene expression profiling was analyzed in freshly isolated
CD133+/CD34+ UCB cells prior to cultivation (day 0)
and after 7 days in culture either with or without 1h-treat-
ment with 10 nM E2. Independent microarray hybridiza-
tions were carried out for each UCB sample, in duplicates,
with oligonucleotide microarrays representing approxi-
mately 20,000, and 55,000 human transcripts (Code-
Link™ Bioarrays, GE Healthcare), following the
manufacturer's protocol. Detailed descriptions of these
Bioarray platforms are publicly available, according to
MIAME guidelines, at the GEO database under the acces-
sion numbers GPL2895 and GPL2891. Briefly, total RNA
was extracted with RNeasy spin columns and treated with
RNAse free-DNAse (Qiagen). One microgram of total
RNA was reverse transcribed in the presence of T7- oligo
dT primer. The resulting cDNA was used for in vitro tran-
scription reaction using T7 RNA polymerase and bioti-
nylated dUTP. Ten micrograms of target cRNA was
fragmented at 94°C for 20 min and hybridized to the bio-
arrays at 37°C for 18 h, under 300 rpm agitation. After
staining with streptavidin-conjugated Cyanine-5 dye, the
slides were washed and fluorescence was measured using
an Axon GenePix 4000B Scanner (Axon Instruments Inc).
Gene Expression measurement
The fluorescent images were captured using GenePix Pro
v.4.1 (Axon Instruments Inc) and the light intensities were
quantified, corrected for background noise, and normal-
ized with the CodeLink™ Expression Analysis v4.1. Spots
with background contamination, shape irregularity, or
pixel saturation were filtered out. Only spots flagged as
"good" (G) or "low" (L) were considered in the subse-
quent analysis. Although the CodeLink™ system is a one-
color platform, we grouped the meaningful comparisons
in pairs to form ratios, as usual in two-color co-hybridized
microarray platforms. The results were analyzed in the MS
space, where M = log2(expression ratio) and S =
log2(mean intensity) [36]. Raw data and normalized
hybridization data are available according to MIAMECancer Cell International 2007, 7:11 http://www.cancerci.com/content/7/1/11
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guidelines at the GEO database, under the accession
number GSE4609.
Differential expression detection
Differentially expressed genes were identified according to
the HTself method [37] which takes advantage of self-self
experiments to define an intensity-dependent fold-change
cutoff. Since our microarray system is a one-color plat-
form, we built virtual experiments combining two repli-
cates of actual hybridizations. We performed three
independent self-self experiments and defined a fold-
change cutoff with 99% credibility level using a window
size and pace of 1.2 and 0.5, respectively, in the S axis [see
Additional file 1]. We considered a gene as differentially
expressed if all its replicates were above (up-regulated) or
below (down-regulated) the dynamic cutoff level defined
by the self-self experiments.
Gene Enrichment and Functional Annotation Analysis
Given the lists of differentially expressed genes, we per-
formed an ontology term enrichment analysis [38] using
the DAVID 2.1 tool to find gene functional classes specif-
ically associated with those lists [39]. In such analysis, the
statistical association between being differentially
expressed and belonging to a given category is accessed by
the Fisher Exact test. The ontologies used were those
defined by the KEGG database of metabolic pathways
[40] and by the Gene Ontology Consortium [41]. The
probe-to-GO and the probe-to-KEGG mapping were
established based on the official annotation provided by
the manufacturer. The analysis of gene expression levels in
cancer and corresponding normal tissue was performed in
silico using the SAGE Anatomic Viewer tool of the SAGE
genie database [42].
Real-time PCR quantification
Peripheral blood samples from 10 CML patients and 5
healthy volunteers were obtained after written informed
consent approved by the Albert Einstein Hospital Internal
Review Board. Mononuclear cells were purified for total
RNA extraction as described above. One microgram of
total RNA was used to synthesize cDNA by extension with
oligo-dT primers and 200U of Superscript II Reverse Tran-
scriptase (Invitrogen Life Technologies). Quantitative
reverse-transcription polymerase chain reaction was per-
formed by the Sybr-Green approach. Normalization of
quantitative data was based on the expression of the
housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). Amplification specificity was assessed
by dissociation curve analysis. Quantification was based
on standard curves established with serial sample dilu-
tions. Primer sequences and amplification conditions are
provided [see Additional file 2].
Statistical analysis
Median, mean, and standard deviation (SD) were calcu-
lated with Excel (Microsoft, Seattle, WA). Statistically sig-
nificant differences among treatments were determined
by the Student t test. All conclusions are based on at least
1% level of significance (P < 0.01) [43].
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